Oxford, UK, March 21st, 2012
Fintan Walton talks exclusively to Johnson & Johnson (J&J) and GlaxoSmithKline (GSK) about their participation in Index Ventures’ latest fund announced today at BIO-Europe Spring in Amsterdam. This €150m fund includes investments from several of Index’s largest existing limited partners and two companies, GSK and the venture capital affiliate of the Janssen pharmaceutical companies of J&J (Janssen).
Francesco De Rubertis of Index Ventures, Dr Moncef Slaoui, Chairman of R&D at GSK and Dr Paul Stoffels, Worldwide Chairman of Johnson & Johnson Pharmaceuticals describe how the two global pharmaceutical companies will share their expertise by participating in the scientific advisory board (SAB) of the fund.
Index will maintain full decision making rights to the portfolio companies and the fund rules and procedures will follow previous Index Ventures funds. This unique pharma/venture partnership model is intended to stimulate promising, early-stage R&D innovation.
For further information, contact:
Fintan Walton
CEO
PharmaVentures
+44 1865 332700
– ends –